Global Vaccine Partnerships
Requirements
Mutual Agreement to Participate: Member organizations and ISV must mutually consent to join the GVP program, ensuring voluntary commitment from both parties.
Promotional Display on Websites: Member organizations and ISV shall feature each other’s logos, and links to each other’s websites to enhance visibility.
Notification for Annual Congress: ISV should inform member organizations the opportunity to join ISV annual congress as a sponsor, oral and poster presenters and other roles.
Advance Awareness of Other Activities: Member organizations can provide early notification of vaccine-related projects or initiatives, granting priority opportunities for involvement or contribution.
Sharing of Resources and Expertise: Member organizations can share or exchanging resources, knowledge, and expertise in vaccine R&D, manufacturing, training and other related areas.
Joint Efforts: Member organizations are encouraged to collaborate in developing and promoting jointly interesting projects at regional or global levels.
Regular Communication: GVP will organize member specific virtual conferences or other activities to promote GVP and its members.
Partners:
International AIDS Society IAS
Global HIV Vaccine Enterprise
The International AIDS Society (IAS) is the world’s largest association of HIV professionals, bringing together scientists, clinicians, policymakers, and advocates to advance HIV research, influence global policy, and ensure equitable access to prevention, treatment, and care. Through major conferences and evidence-based initiatives, IAS drives the global response to end AIDS as a public health threat. Co-organizer of the ISV Mini-Symposium on HIV Vaccines (June 2025)
International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a treaty-based international organization established in 1997 with a not-for-profit mission to discover, develop, and deliver safe, effective, and affordable vaccines—empowering vaccine equity, impact, and sustainability globally. Co-organizer of ISV Congress 2024 and Partner for ISV Congress 2025
IVVN International Veterinary Vaccinology Network from the UK
The IVVN seeks to kindle and foster these essential collaborations. With our unique remit, we aim to help researchers, industrial partners and others work together towards developing vaccines specifically for high-consequence livestock (including poultry and aquaculture) diseases in LMICs. Partner for ISV Congress 2024 & 2025
Immunity for Health
Immunity for Health provides a unique platform that connects diverse stakeholders while offering access to expertise, cutting-edge technologies, and essential resources to advance vaccine research and development. Sponsor of ISV 2019 Congress
University of Texas Medical Branch at Galveston
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Instituto Butantan from Brazil
With 123 years of history, Butantan works to prevent diseases like Covid-19, flu, tetanus, diphtheria, hepatitis A and B, chikungunya, whooping cough, dengue, HPV and rabies.
Vaccine Innovative Technology ALliance (VITAL)-Korea
Vaccine Innovative Technology ALliance Korea (VITAL-Korea) is a Korean government-backed initiative launched in April 2020, under the support of the Ministry of Health and Welfare, with the mission to strengthen national vaccine self-sufficiency, accelerate vaccine candidate discovery, and drive translation into clinical development and global deployment.
Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa)
cSIMVa is a research institute at Chiba University that is dedicated to advancing our understanding of the mucosal immune system and developing innovative mucosal vaccines. Mucosal vaccines, including oral and nasal vaccines, show great promise as preventive vaccines, with the potential to not only prevent infection, but also reduce disease severity.
